| Literature DB >> 17965760 |
Abstract
Irrespective of the presence of cytotoxic acetogenins and styryl-lactones in the genus Goniothalamus, only 22 species in the genus Goniothalamus, out of 160 species (13.7%) have so far been investigated. In an effort to promote further research on the genus Goniothalamus which could represent a source of drugs for the treatment of cancers and bacterial infections, this work offers a broad analysis of current knowledge on Goniothalamus species. Therefore, it includes (i) taxonomy (ii) botanical description (iii) traditional medicinal uses and (iv) phytochemical and pharmacological studies. We discuss the molecular mechanisms of actions of acetogenins and styryl-lactones, with some emphasis on the possible involvement of protein kinase, Bax and TRAIL receptors in the cytotoxic effects of styryl-lactones. We also report (v) the growth inhibition of several nosocomial bacteria by Goniothalamus. scortechinii. The crude methanol extract of G. scortechinii showed a good and broad spectrum of antibacterial activity against both Gram-negative and Gram-positive bacteria.Entities:
Keywords: Goniothalamus; Goniothalamus scortechinii; acetogenins; antibacterial; antifungal; apoptosis; cytotoxic; foodborn bacteria; nosocomial; styryl-lactones.
Year: 2007 PMID: 17965760 PMCID: PMC1978243 DOI: 10.1093/ecam/nem009
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1.Acetogenins from Goniothalamus species.
Antitumor activity of Goniothalamus species
| Species | Chemical component | Cells | Dose | Cell cycle/apoptosis |
|---|---|---|---|---|
| 4-Deoxyanomontacin ( | A-549 | 6.45 × 10−7 μg/ml | ||
| MCF-7 | 5.77 × 10−7 μg/ml | |||
| HT-29 | 1.41 × 10−1 μg/ml | |||
| A-498 | 1.50 × 10−1 μg/ml | |||
| PC-3 | 1.73 × 10−1 μg/ml | |||
| PACA-2 | 1.×10−5 μg/ml | |||
| (2,4- | HT-29 | 2.55 × 10−1 μg/ml | ||
| PACA-2 | 6.78 × 10−1 μg/ml | |||
| A-549 | 5.99 × 10−2 μg/ml | |||
| MCF-7 | 2.68 × 10−1 μg/ml | |||
| HT-29 | 6.94 × 10−6 μg/ml | |||
| A-498 | 1.39 × 10−2 μg/ml | |||
| PC-3 | 1.11 × 10−1 μg/ml | |||
| PACA-2 | 1.15 × 10−1 μg/ml | |||
| 4-Acetylgigantetrocin ( | A-549 | <10−2 μg/ml | ||
| MCF-7 | 8.5 × 10−1 μg/ml | |||
| HT-29 | <10−2 μg/ml | |||
| A-498 | 1.55 × 10−1 μg/ml | |||
| PACA-2 | <10−2 μg/ml | |||
| Annonacin ( | PA1 | 0.452 μg/ml | G1 | |
| SKOV3 | 0.411 μg/ml | |||
| HeLa | 0.219 μg/ml | |||
| HeLa S3 | 0.426 μg/ml | |||
| MCF-7 | 0.433 μg/ml | |||
| T-24 | 0.324 μg/ml | |||
| BCC-1 | 0.427 μg/ml | |||
| Gigantransenin A ( | A-549 | 0.16 μg/ml | ||
| Gigantransenin B ( | A-549 | 0.21 μg/ml | ||
| MCF-7 | 2.1 × 10−1 μg/ml | |||
| Gigantrasenin C ( | A-549 | 0.18 μg/ml | ||
| Goniotetrocin ( | A-549 | 3.9 10−1 μg/ml | ||
| PC-3 | 2.1 10−1 μg/ml | |||
| PACA-2 | 2.6 10−2 μg/ml | |||
| (2,4- | ||||
| Gonioneninone ( | PACA-2 | 4.5 10−2 μg/ml | ||
| Goniothalamicin ( | A-549 | 2.8010−1 μg/ml | ||
| Gonionenine ( | PACA-2 | 4.5 10−1 μg/ml | ||
| Pyranicin ( | A-549 | 2.8 10−1 μg/ml | ||
| MCF-7 | 3.6 × 10−1 μg/ml | |||
| A-498 | 1.8 × 10−1 μg/ml | |||
| PACA-2 | 1.3 10−3 μg/ml | |||
| Deoxyannomontacin ( | A-549 | 6.45 10−7 μg/ml | ||
| MCF-7 | 1.41 × 10−1 μg/ml | |||
| A-498 | 1.50 × 10−1 μg/ml | |||
| PACA-2 | 1.5 10−5 μg/ml | |||
| Annomontacinone ( | HT-29 | 2.55 × 10−1 μg/ml | ||
| Annomontacinone ( | PACA-2 | 6.78 × 10−1 μg/ml | ||
| Pyragonicin ( | A-549 | <10−2 μg/ml | ||
| HT-29 | 3.4 10−1 μg/ml | |||
| A-498 | 1.55 × 10−1 μg/ml | |||
| PACA-2 | 5.8 10−3 μg/ml | |||
| Goniotrionin ( | A-549 | 7.7 10−3 μg/ml | ||
| MCF-7 | 8.5 × 10−1 μg/ml | |||
| MCF-7 | 5.3 10−6 μg/ml | |||
| A-498 | 2.10−3 μg/ml | |||
| PC-3 | 3.6 10−1 μg/ml | |||
| PACA-2 | 5.4 10−3 μg/ml | |||
| Goniodonin ( | HCT-8 | <10 μg/ml | ||
| Donhexocin ( | HCT-8 | 0.82 μg/ml | ||
| Donbutocin ( | L1210 | 0.81 μg/ml | ||
| Gardnerilin A ( | Bel7402n | 3.6 μg/ml | ||
| Gardnerilin B ( | Bel7402 | 8.5 μg/ml | ||
| Goniothalamin ( | HL-60 | apoptosis | ||
| Jurkat T | apoptosis | |||
| Goniothalamin ( | HepG2 | 8.83 μM | G2/apoptosis | |
| HepG2R | 8 μM | |||
| Altholactone ( | HepG2 | 0.7 μM | apoptosis | |
| HepG2R | 6.17 μM | |||
| Goniodiol ( | HepG2 | 10 μM | G2 | |
| HepG2R | 8.33 μM | |||
| Altholactone ( | HL60 | apoptosis | ||
| Goniothalamin ( | P388 | 0.75 μg/ml | ||
| WEHI164 | 1.70 μg/ml | |||
| MOLT-4 | <1 μg/ml | |||
| Howiinol ( | L1210 | 6.85 μg/ml | G1 | |
| Goniolactone B ( | A2780 | 7.40 μM | ||
| HCT-8 | 4.43 μM | |||
| KB | 7.23 μM | |||
| Synthesized | Goniothalamin ( | MCF-7 | 10.5 μM | |
| HT-29 | 11.2 μM |
ahuman lung carcinoma; bhuman breast carcinoma; chuman colon adenocarcinoma; dhuman kidney carcinoma, ehuman prostate adenocarcinoma, fhuman pancreatic carcinoma, g,hovarian cancer cells; I,jcervical cancer; kbladder cancer; lskin cancer, mhuman colon adenocarcinoma, nhepatoma cell-line, oleukemia cells, ppromyelocytic leukemia cells; qEhrlich ascites tumor cells.
Figure 2.Hypothetical molecular mode of action of bullatacin against Complex I. MM: Mitochondrial Matrix, MIN: Mitochondrial Inner Membrane; IS: Intermembrane Space.
Figure 3.Styryl-lactones from Goniothalamus species.
Figure 4.Note the proximity of chemical structure between flavokavain A, an inhibitor of protein kinase, and goniothalamin. What is the precise activity of styryl lactones against protein kinases?.
Figure 5.Putative mechanism of action of Goniothalamus styryl-lactones in apoptosis. TRAIL R: TRAIL receptor, Cyt. c: Cytochrome c; C: caspases. 1: styryl-lactone interacts with cellular kinase, 2: kinase mediation of TRAIL induction of apoptosis, 3: TRAIL induced translocation of Bax to mitochondria, 4, 5: release of cytochrome C and activation of caspases, SMAC/Diablo, EndoG, 6: chromatin condensation and cellular death.
Antibacterial activity of extractives from G. scortechinii
| H | D | A | M | S | N | |
|---|---|---|---|---|---|---|
| Gram-positive bacteria | ||||||
| 13 | 20 | – | 20 | 18 | ||
| 14 | 27 | – | 21 | 16 | ||
| 14 | 23 | – | 20 | 16 | ||
| – | 20 | – | 14 | 14 | ||
| – | 21 | – | 13 | 10 | ||
| Gram-negative bacteria | ||||||
| – | – | – | – | 17 | ||
| – | 19 | 10 | 13 | 20 | ||
| – | 11 | – | – | 20 | ||
| 16 | 28 | – | 18 | 20 | ||
| – | 13 | 7 | – | 13 | ||
| – | 17 | 12 | 10 | 20 | ||
| Yeast | ||||||
| 13 | 23 | – | 9 | 17 |
Average zone of inhibition (in mm) of triplicate including the diameter of the filter paper disc (6 mm). H = hexane fraction (5 mg/disc) D = dichloromethane fraction (5 mg/disc) A = aqueous fraction (5 mg/disc) M = methanol fraction (5 mg/disc) S = streptomycin (10 μg/disc) N = Nystatin (100 IU).
Figure 6.Antibacterial activity of G. scortechinii against Klebsiella pneumoniae.